Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults

Neurocritical Care

Volumn 20, Issue 1, 2014, Pages 158-171

  Ng, Karen ^a   Mabasa, Vincent H ^b   Chow, Ivy ^b   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BURNLEY GENERAL HOSPITAL   (United Kingdom)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Intraventricular; Meningitis; Therapeutic drug monitoring; Vancomycin; Ventriculitis

Indexed keywords

ANTIBIOTIC AGENT; CEFALOTIN; CEFOXITIN; CEPHALOSPORIN; CIPROFLOXACIN; CYCLOSPORIN; FUSIDIC ACID; METRONIDAZOLE; PREDNISONE; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ATAXIA; BRAIN VENTRICULITIS; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; DEVICE REMOVAL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; HEADACHE; HEARING IMPAIRMENT; HUMAN; HYDROCEPHALUS; LEUKOCYTOSIS; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHUNT INFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION; CEREBRAL VENTRICULITIS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MENINGOENCEPHALITIS;

ANTI-BACTERIAL AGENTS; CEREBRAL VENTRICULITIS; HUMANS; INJECTIONS, INTRAVENTRICULAR; MENINGOENCEPHALITIS; VANCOMYCIN;

EID: 84894549719     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-012-9784-z     Document Type: Review

References (33)

1. Cook AM, Mieure DK, Owen RD, Pesaturo AB, Hatton J. Intracerebroventricular administration of drugs. Pharmacotherapy. 2009;29(7):832-45.
2. Tunkel AR, et al. Practice guidelines for bacterial meningitis. Clin Infect Dis. 2004;39(1):1267-84.
3. Agrawal A, Cincu R, Timothy J. Current concepts and approach to ventriculitis. Infect Dis Clin Prac. 2008;16(2):100-4.
4. Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis. 1998;27(5):1117-27.
5. Luer MS, Hatton J, Maldonado WT, Fiset C. Vancomycin administration into the cerebrospinal fluid: a review. Ann Pharmacother. 1993;27(7-8):912-21.
6. Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858-83.
7. U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force, 2nd ed. Baltimore, MD: Williams & Wilkins; 1996.
8. Ziai WC, Lewin JJ. Improving the role of intraventricular antimicrobial agents in the management of meningitis. Curr Opin Neurol. 2009;22(3):277-82.
9. Viladrich PF, Gudiol F, Linares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother. 1991;35:2467-72.
10. Cabellos C, MartAnez-Lacasa J, Martos A, et al. Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Antimicrob Agents Chemother. 1995;39:2158-60.
11. Collins JM. Pharmacokinetics of intraventricular administration. J Neurooncol. 1983;1:283-91.
12. Arroyo JC, Quindlen EA. Accumulation of vancomycin after intraventricular infusions. South Med J. 1983;76(12):1554-5.
13. Richards SJ, Lambert CM, Scott AC. Recurrent listeria monocytogenes meningitis treated with intraventricular vancomycin. J Antimicrob Chemother. 1992;29(3):351-3.
14. Czaban SL, Lebkowski WJ, Krajewski JP, Borkowski J. The efficacy of intraventricularly administered vancomycin in the case of central nervous system infection caused by Enterococcus faecalis. Wiadomosci Kelarskie. 2002;55(9-10):617-25.
15. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am. 1999;13(3):595-619.
16. Bayston R, Hart CA, Barnicoat M. Intraventricular vancomycin in the treatment of ventriculitis associated with cerebrospinal fluid shunting and drainage. J Neurol Neurosurg Psychiatry. 1987;50(11):1419-23.
17. Amod F, Moodley I, Peer AKC, Sunderland J, Lovering A, Wootton M, Nadvi S, Vawda F. Ventriculitis due to a hetero strain of vancomycin intermediate Staphyloccocus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin. J Infect. 2005;50:252-7.
18. Schwabe M, Juttner E, Blaiche A, Potthoff K, Pisarski P, Walker CF. Cure of ventriculitis and central nervous system shunt infection by Staphylococcus epidermidis with vancomycin by intraventricular injection in a liver transplant patient. Transpl Infect Dis. 2007;9:46-50.
19. Sutherland GE, Palitang EG, Marr JJ, Luedke SL. Sterilization of ommaya reservoir by instillation of vancomycin. Am J Med. 1981;71:1068-70.
20. Bayston R, Barnicoat M, Cudmore RE, Guiney EJ, Gurusinghe N, Norman PM. The use of intraventricular vancomycin in the treatment of CSF shunt-associated ventriculitis. Zeitschrift fur Kinderchirurgie. 1984;39(Suppl 2):111-3.
21. Swayne R, Rampling A, Newsom SWB. Intraventricular vancomycin for treatment of shunt-associated ventriculitis. J Antimicrob Chemother. 1987;19:249-53.
22. Reesor C, Chow AW, Kureishi A, Jewesson PJ. Kinetics of intraventricular vancomycin in infections of cerebrospinal fluid shunts. J Infect Dis. 1988;158(5):1142-3.
23. Pfausler B, Spiss H, Beer R, Kampl A, Engelhardt K, Schober M, Schmutzhard E. Treatment of Staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg. 2003;98(5):1040-4.
24. Young EJ, Ratmer RE, Clarridge JE. Staphylococcal ventriculitis treated with vancomycin. South Med J. 1981;74:1014-5.
25. Pfausler B, Haring HP, Kampfl A, Wissel J, Schober M, Schmutzhard E. Cerebrospinal fluid (CSF) pharmacokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. Clin Infect Dis. 1997;25(3):733-5.
26. Morales-Garcia VD, Garza-Mercado R, Tamez-Montes D, Martinez-Ponce DLA. Efficacy of prophylactic intraventricular vancomycin in patients with ventriculostomy. Arch Neurosci. 2005;10(3):128-32.
27. LeRoux P, Howard MA III, Winn HR. Vancomycin pharmacokinetics in hydrocephalic shunt prophylaxis and relationship to ventricular volume. Surg Neurol. 1990;34:366-72.
28. Hirsch BE, Amodio M, Einzig AI, Halevy R, Soeiro R. Instillation of vancomycin into a cerebrospinal fluid reservoir to clear infection: pharmacokinetic considerations. J Infect Dis. 1991;163(1):197-200.
29. Pope SD, Roecker AM. Vancomycin for treatment of invasive multi-drug resistant Staphylococcus aureus infections. Expert Opin Pharmacother. 2007;8(9):1245-61.
30. Breeze RE, McComb JG, Hyman S, Gilles FH. CSF production in acute ventriculitis. J Neurosurg. 1989;70(4):619-22.
31. Inamasu J, Kuramae T, Tomiyasu K, Nakatsukasa M. Fulminant ependymitis following intraventricular rupture of brain abscess. J Infect Chemother. 2011;17:534-7.
32. Nau R, Sorgel F, Prange HW. Pharmacokinetic optimization of the treatment of bacterial central nervous system infections. Clin Pharmacokinet. 1998;35(3):223-46.
33. Ensom MHH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century: does the evidence support definitive-outcomes? Clin Pharmacokinet. 1998;34(4):265-79.